Robust Guidelines for the Management of HR+ Her2− EBC: Crucial Value of CanAssist Breast

1Department of Medical & HematoOncology, Cancer Institute, Medanta Hospital, Gurugram, Haryana, India 2Department of Medical Oncology & BMT, Apollo Hospital, Chennai, Tamil Nadu, India 3Department of Medical Oncology, Rajiv Gandhi Cancer Institute, New Delhi, India 4Department of Medical Oncology, AIG Hospital, Hyderabad, Telangana, India 5Department of Medical Oncology, Kovai Medical Center and Hospital, Coimbatore, Tamil Nadu, India 6Department of Medical Oncology, Hemato Oncology and BMT, Cytecare Hospital, Bengaluru, Karnataka, India 7Department of Medical Oncology, Hope Cancer Clinic, New Delhi, India

[1]  C. Seynaeve,et al.  9P Long term recurrence risk predictions by CanAssist breast in a sub-cohort of TEAM trial , 2022, Annals of Oncology.

[2]  G. Bhattacharyya,et al.  Practical Consensus Recommendations for Optimizing Risk versus Benefit of Chemotherapy in Patients with HR Positive Her2 Negative Early Breast Cancer in India , 2021, South Asian Journal of Cancer.

[3]  S. Pasricha,et al.  IHC versus FISH versus NGS to detect ALK gene rearrangement in NSCLC: all questions answered? , 2021, Journal of Clinical Pathology.

[4]  K. Babu,et al.  South Asian Declaration—Consensus Guidelines for COVID-19 Vaccination in Cancer Patients , 2021, South Asian Journal of Cancer.

[5]  D. Doval,et al.  Shared Decision-Making and Medicolegal Aspects: Delivering High-Quality Cancer Care in India , 2020, Indian journal of palliative care.

[6]  J. Olson,et al.  Race, ethnicity and clinical outcomes in hormone receptor-positive, HER2-negative, node-negative breast cancer in the randomized TAILORx trial. , 2020, Journal of the National Cancer Institute.

[7]  D. Doval,et al.  A multi-institutional real world data study from India of 3453 non-metastatic breast cancer patients undergoing upfront surgery , 2020, Scientific Reports.

[8]  A. Batra,et al.  Oncotype DX: Where Does It Stand in India? , 2019, Journal of global oncology.

[9]  D. Doval,et al.  Clinical validation of an immunohistochemistry‐based CanAssist‐Breast test for distant recurrence prediction in hormone receptor‐positive breast cancer patients , 2019, Cancer medicine.

[10]  D. Doval,et al.  Development of a Novel Proteomic Risk-Classifier for Prognostication of Patients With Early-Stage Hormone Receptor–Positive Breast Cancer , 2018, Biomarker insights.